Helical Tomotherapy for Simultaneous Multitarget Radiotherapy for Pulmonary Metastasis

Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours

“…5,6 While dosimetric findings have shown that such capabilities can potentially translate into the delivery of an increased tumour dose with doses to normal tissues decreased compared with other techniques, 7,8 only a limited number of patients were included in recent studies that have addressed the feasibility of hypofractionated or ablative radiotherapy (RT) regimens for lung tumours treated with HT. [9][10][11][12][13][14][15][16] Reasonable arguments might be advocated for its slow adoption in the clinical practice in this setting: during HT it is not only the tumour and the MLC that are moving but also the radiation source and couch, which can maximize the breathing interplay effect (i.e. difference between planned and delivered absorbed doses that arises from a mismatch between the tumour and the MLC because of motion).…”

“…Median overall survival (OS) and progression-free survival (PFS) for the entire population were 30.8 and 14.1 months, respectively. At multivariate analysis (MVA), BED 10 $ 100 Gy and KPS $ 90 emerged as significant prognostic factors for OS (p 5 0.01 and p 5 0.001, respectively), and BED 10 $ 100 Gy for PFS (p 5 0.02). Conclusion: Our findings show that HHT adjusted for tumour location and/or target volume is an effective treatment with an acceptable toxicity profile in patients who are medically inoperable with lung tumours and is not associated with a specific pattern of lung injury.…”

“…Dose prescription was driven by tumour location (hilar/pericentral vs peripheral) and/or target volume. 52% of the lesions received a biological equivalent dose (BED 10 ) $100 Gy. Assessment of tumour response was based on the Response Evaluation Criteria in Solid Tumours 1.1 criteria coupled with fluorine-18 fludeoxyglucose/positron emission tomography-CT.…”

Curative Radiotherapy in Metastatic Disease: How to Develop the Role of Radiotherapy from Local to Metastases

“…Kim et al also treated the patients with multiple lung metastases with SBRT to a dose of 50 Gy in 10 fractions during 2 weeks. The local control rate was 87.1% and median survival time was 16.0 months (Kim et al, 2009). Two prospective studies' outcomes were also shown in table 3.…”

Usefulness Evaluation on the Treatment Plan of Tomotherapy and VMAT in Radiotherapy for Prostate Cancer

“…이 를 보완하기 위해 다엽콜리메이터(multi leaf collimator, MLC)를 이용한 세기변조방사선치료(intensity modulated radiotherapy, IMRT)가 도입되었다 [3], [4] . 전립선암 방사선 치료에 운영되고 있다 [5], [6] . 최근 2011 년 7월에 전립선암, 뇌종양, 두경부암, 척추암, 재발암 과 함께 국민건강보험급여가 적용되면서 더욱 증가하 고 있다 [7] .…”